|
KMID : 0861020170320010015
|
|
Korea Journal of Herbology
2017 Volume.32 No. 1 p.15 ~ p.23
|
|
|
Improvement Effect of Sibjotang on Blood Glucose and Renal Dysfunction in Type II Diabetic Mice
|
|
Yoon Jung-Joo
Lee Yun-Jung
Kim Hye-Yoom
Ahn You-Mee
Jin Xian-Jun
Hong Mi-Hyeon
Hwang Jin-Seok
Lee Ho-Sub
Kang Dae-Gill
|
|
|
Abstract
|
|
|
Objectives : It is well known that Sibjotang (Shizaotang), traditional herbal medicine formula, regulates the body fluid blood pressure homeostasis. This study is to investigate whether Sibjotang improves diabetic renal dysfunction in type II diabetes mellitus animal model, db/db mice.
Methods : The animals model were divided into three groups at the age of 8 weeks; control group (C57BLKS/J-db/m mice), diabetic group [(C57BLKS/J+Lepr)-db/db mice], and Sibjotang group [(C57BLKS/J+Lepr)-db/db mice + Sibjotang 100 ㎎/㎏/day]. During 8 weeks of treatment, blood glucose and urinary albumin excretion were checked in metabolic chamber at 8, 12, and 16 weeks of age, respectively.
Results : Body weight and food intake of diabetic group were significantly higher than control group after 8 weeks administration. However, there were not significant different between the diabetic group and Sibjotang group. Urinary albumin excretion was significantly decreased in the Sibjotang group than the diabetic group. In addition, supplementation with Sibjotang significantly lowered levels of blood glucose, insulin, and homeostatic model assessmentinsulin resistance (HOMA-IR), suggesting reduced insulin resistance. The ratio of mesangial matrix/glomerular area was markedly larger in diabetic group than control group, whereas Sibjotang significantly reduced this expansion. Moreover, immunohistological study revealed that Sibjotang attenuated the increase of transforming growth factor(TGF)-β expression in kidney.
Conclusion : Sibjotang ameliorates diabetes-associated renal injury through the improvement of the blood glucose and insulin sensitivity, and inhibiting the TGF-β1 expression. Therefore, Sibjotang may be a new therapeutic formula for the treatment of diabetic-associated renal dysfunction.
|
|
|
KEYWORD
|
|
|
Sibjotang, db/db mice, Blood glucose, TGF-β1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|